Arizona Clinical Trials Report — May 2026

For Arizonans considering participation in clinical research, May 2026 presents a critical window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 1,704 clinical trials are currently recruiting, but a significant number are closing soon. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Time is Running Out: Trials Closing Soon Across Arizona

A total of 111 clinical trials in Arizona are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 14 of these rapidly closing studies actively seeking participants without specific health conditions. If you've been considering participating in a trial, now is the time to act, especially if your interests align with the conditions listed below.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on metabolic health, neurological disorders, and chronic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Obesity
• Myasthenia gravis
• End stage liver disease
• Alzheimer disease
• Migraine
• Major depressive disorder
• Advance care planning
• Adjustment disorders
• Acromegaly
• Advanced solid tumors

These trials offer a chance to engage with potential new treatments and contribute to understanding these conditions before their enrollment windows close.

Spotlight on New Research: Major Phase 3 Trials Launch

This month, Arizona saw the opening of 5 new clinical trials. While this number is lower compared to the 21 trials that launched in March 2026, the new additions include several high-profile Phase 3 studies from major pharmaceutical companies, offering significant opportunities for participants.

These notable trials represent substantial investments in medical research, focusing on widespread health challenges:

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial global trial aims to enroll 5,610 participants, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Immuneering Corporation is leading NCT07562152, a Phase 3 study titled "Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma." This trial aims to enroll 510 participants, evaluating the safety and efficacy of atebimetinib in combination with modified GnP compared with standard of care GnP alone for metastatic pancreatic adenocarcinoma.
• The third Phase 3 study from Novo Nordisk A/S this month is NCT07571109, "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea." This study will involve 300 participants to look at the efficacy and safety of NNC0487-0111 in individuals with overweight or obesity and obstructive sleep apnoea treated with positive airway pressure.

These new studies primarily focus on drug interventions, with 4 classified as drug trials and 1 as a behavioral study. The conditions targeted by this month's new trials include:

• Obesity
• Lung cancer
• Obstructive sleep apnoea
• Overweight
• Pancreatic adenocarcinoma (including metastatic and ductal adenocarcinoma)

Notably, Novo Nordisk A/S is a prominent sponsor this month, leading 3 of the new trials, with Immuneering Corporation sponsoring 1 and the University of Arizona sponsoring the remaining 1.

Arizona's Research Footprint: Where to Find Trials

Arizona continues to be a hub for clinical research, with a total of 1,704 clinical trials currently recruiting across 44 cities and 1,139 research sites. This broad distribution ensures that opportunities are accessible to residents throughout the state, not just in major metropolitan areas.

This month's new trials show a clear concentration in the state's larger urban centers. The cities where new trials opened include:

• Gilbert (3 new trials)
• Phoenix (3 new trials)
• Glendale (1 new trial)
• Tucson (1 new trial)

This distribution highlights the active research environments in the Phoenix metropolitan area and Tucson, offering convenient access for many Arizonans.

Opportunities for All: Healthy Volunteers and Specific Demographics

While 0 of the 5 new trials opened this month are accepting healthy volunteers, there are still significant opportunities for individuals without specific health conditions to contribute to medical research. Across Arizona, a total of 147 trials are currently recruiting healthy participants. As mentioned earlier, 14 of these healthy volunteer trials are closing within the next 90 days, so prompt action is encouraged.

Regarding specific demographics, all 5 of the new trials opened this month include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials this month are exclusively for children, females, or males.

Looking ahead, the ongoing enrollment in these significant Phase 3 trials, particularly those addressing obesity and heart conditions, will be a key focus. Researchers will continue to work towards advancing medical knowledge and developing new treatments for a wide range of health challenges across Arizona.